Cipro Buyers Say Cos. Are Denying 'Stark Reality' Of Actavis

Law360, New York (February 20, 2014, 7:31 PM EST) -- A group of Cipro purchasers trying to convince California's highest court to revive their pay-for-delay antitrust case against several generic-drug makers accused the companies last week of trying to deny the reality of the U.S. Supreme Court's recent ruling paving the way for challenges to the patent settlements.

The drugmakers — Barr Laboratories Inc., Hoechst Marion Roussel Inc., The Rugby Group Inc. and Watson Pharmaceuticals Inc. — have argued that the justices' decision in FTC v. Actavis rejected the notion that pay-for-delay settlements should be presumed anti-competitive....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.